reports
Aktietilbagekøb i Danske Bank: Transaktioner i uge 33
Aktietilbagekøb i Danske Bank: Transaktioner i uge 33 Selskabsmeddelelse nr. 38 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 018. august 2025Page 1 of 1Aktietilbagekøb i Danske Bank: Transaktioner i uge 33Den 7. februar 2025, offentliggjorde Danske Bank A/S et aktietilbagekøbsprogram for samlet 5 mia. kr. med maksimalt 45.000.000 aktier i perioden fra 10. februar 2025 til senest 30. januar 2026 - som beskrevet i selskabsmeddelelse nr. 6 2025. Aktietilbagekøbsprogrammet gennemføres i henhold til artikel 5 i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. apr...
Danske Bank share buy-back programme: transactions in week 33
Danske Bank share buy-back programme: transactions in week 33 Company announcement no. 38 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 018 August 2025Page 1 of 1Danske Bank share buy-back programme: transactions in week 33On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the Europe...
Danske Bank AS: 1 director
A director at Danske Bank AS sold 55,050 shares at 269.600DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 14. august 2025 Indberetning nr. 57/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Head of Group Corporate Communicat...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 14 August 2025 Notification no. 57/2025 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: St...
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 12, 2025 – (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million....
Aktietilbagekøb i Danske Bank: Transaktioner i uge 32
Aktietilbagekøb i Danske Bank: Transaktioner i uge 32 Selskabsmeddelelse nr. 37 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 011. august 2025Page 1 of 1Aktietilbagekøb i Danske Bank: Transaktioner i uge 32Den 7. februar 2025, offentliggjorde Danske Bank A/S et aktietilbagekøbsprogram for samlet 5 mia. kr. med maksimalt 45.000.000 aktier i perioden fra 10. februar 2025 til senest 30. januar 2026 - som beskrevet i selskabsmeddelelse nr. 6 2025. Aktietilbagekøbsprogrammet gennemføres i henhold til artikel 5 i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april...
Danske Bank share buy-back programme: transactions in week 32
Danske Bank share buy-back programme: transactions in week 32 Company announcement no. 37 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 011 August 2025Page 1 of 1Danske Bank share buy-back programme: transactions in week 32On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the Europ...
Genmab Announces Financial Results for the First Half of 2025
Genmab Announces Financial Results for the First Half of 2025 August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory FLRinatabart sesutecan (Rina-S®) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual MeetingData from over 40 abstracts highlighting the depth, breadth and strength of Genmab’s comprehensive epcori...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary ...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 5. august 2025 Indberetning nr. 56/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Head of Group Corporate Communicati...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 5 August 2025 Notification no. 56/2025 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Ste...
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 4. august 2025 Indberetning nr. 55/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug For yderligere detaljer henvises til det vedhæftede skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Head of Group Corporate Communications, tel.nr. Vedhæftet fil
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 4 August 2025 Notification no. 55/2025 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. For further details, please find the attached template for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Kailay Wind, Head of Group Corporate Communications, tel. Attachment ...
Aktietilbagekøb i Danske Bank: Transaktioner i uge 31
Aktietilbagekøb i Danske Bank: Transaktioner i uge 31 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Selskabsmeddelelse nr. 36 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 004. august 2025Page 1 of 1Aktietilbagekøb i Danske Bank: Transaktioner i uge 31Den 7. februar 2025, offentliggjorde Danske Bank A/S et aktietilbagekøbsprogram for samlet 5 mia. kr. med maksimalt 45.000.000 aktier i perioden fra 10. februar 2025 til senest 30. januar 2026 - som beskrevet i selskabsmeddelelse nr. 6 2025. Aktietilbagek...
Danske Bank share buy-back programme: transactions in week 31
Danske Bank share buy-back programme: transactions in week 31 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Company announcement no. 36 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 004 August 2025Page 1 of 1Danske Bank share buy-back programme: transactions in week 31On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company ann...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.